Difference between revisions of "Agomelatine-imipramine"

From Psychiatrienet
Jump to: navigation, search
Line 5: Line 5:
 
* Agomelatine can be stopped abruptly for every dosage.
 
* Agomelatine can be stopped abruptly for every dosage.
 
| start =  
 
| start =  
 +
* A wash-out period is not necessary.
 
* Start administration of imipramine the next day in a dosage of 25-75 mg/day.
 
* Start administration of imipramine the next day in a dosage of 25-75 mg/day.
 
* If necessary, increase dosage of imipramine to 150-200 mg/day.}}
 
* If necessary, increase dosage of imipramine to 150-200 mg/day.}}

Revision as of 07:48, 7 May 2009

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine

Switch medication from agomelatine to imipramine.[1] [2]

Nietinrijdenbord.png Stop agomelatine
  • Agomelatine can be stopped abruptly for every dosage.
Eenrichtingbord.png Start imipramine
  • A wash-out period is not necessary.
  • Start administration of imipramine the next day in a dosage of 25-75 mg/day.
  • If necessary, increase dosage of imipramine to 150-200 mg/day.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.